Claims for Patent: 3,681,500

Summary for Patent: 3,681,500

Title:	SPRAY COMPOSITIONS FOR TREATMENT OF OBSTRUCTIVE DISORDERS OF THE RESPIRATORY TRACT AND METHODS THEREFOR
Abstract:	Inhalation spray compositions for the treatment of obstructive disorders of the respiratory tract, comprising as an active ingredient a physiologically compatible quaternary salt of N-isopropyl-N-methyl-nortropine tropic acid ester, optionally in combination with a mucolytic and/or a bronchospasmolytic.
Inventor(s):	Zeile; Karl (Ingelheim am Rhein, DT), Schulz; Werner (Ingelheim am Rhein, DT), Banholzer; Rolf (Ingelheim am Rhein, DT), Wick; Helmut (Ingelheim am Rhein, DT)
Assignee:	Boehringer Ingelheim GmbH (Ingelheim am Rhine, DT)
Application Number:	05/094,951
Patent Claims:	1. The method of reducing the air flow resistance in the respiratory tract of a human patent afflicted with an asthmatic disorder of the respiratory tract, which comprises administering to said patient per inhalationem from 5 to 1,000 .gamma. of a pharmaceutically acceptable quaternary atropinium salt of the formula ##SPC1## 2. The method according to claim 8, where X is the anion of hydrobromic, 3. The method according to claim 8, where X is the anion of hydrobromic 4. The method according to claim 8, which comprises simultaneously administering to said patient per inhalationem and effective bronchospasmolytic amount of a bronchial antispasmodic selected from the group consisting of 1-(3',5'-dihydroxy-phenyl)-1-hydroxy-2-[1"-(p-hydroxy-phenyl)-isopropyl-am ino]-ethane hydrobromide and 5. The method according to claim 8, which comprises simultaneously administering to said patient per inhalationem an effective mucolytic amount of a compound selected from the group consisting of 6. A pharmaceutical inhalation spray composition for treating asthmatic disorders of the respiratory tract, consisting of 0.007 to 1.0 percent weight, based on the total weight of said composition, of a pharmaceutically acceptable quaternary atropinium salt of the formula ##SPC2## wherein X is the anion of an acid, and the balance an aqueous solution of 2 mgm/ml of N-cyclohexyl-N-methyl-2-(2-amino-3,5-dibromo)-benzylammonium 7. A composition according to claim 6, wherein said atropinium salt is 8. A pharmaceutical inhalation spray composition for treating asthmatic disorders of the respiratory tract, consisting of 0.007 to 1.0 percent weight, based on the total weight of said composition, of a pharmaceutically acceptable quaternary atropinium salt of the formula ##SPC3## wherein X is the anion of an acid, and the balance an aqueous solution of 0.2 mgm/ml of a mucolytic selected from the group consisting of 9. A composition according to claim 8, wherein said atropinium salt is 10. A pharmaceutical inhalation spray composition for treating asthmatic disorders of the respiratory tract, consisting essentially of an effective amount of a pharmaceutically acceptable quaternary atropinium salt of the formula ##SPC4## 11. A composition according to claim 10, wherein said non-aqueous liquid carrier is a liquified mixture of monofluoro-trichloro-methane and 12. A composition according to claim 10, wherein said atropinium salt is 13. A composition according to claim 10, which additionally comprises up to 14. A composition according to claim 13, which additionally comprises an effective bronchospasmolytic amount of 1-(3',5'-dhydroxy-phenyl)-1-hydroxy-2-[1"-(p-hydroxy-phenyl)-isopropyl-ami no]-ethan hydrobromide.